[Skip to Navigation]
Sign In
Comment & Response
September 2018

Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer—Reply

Author Affiliations
  • 1Sorbonne Paris Cité, Université Paris Descartes, Department of Gastroenterology and Gastrointestinal Oncology, Hospital Européen Georges Pompidou, Paris, France
JAMA Oncol. 2018;4(9):1298. doi:10.1001/jamaoncol.2018.1718

In Reply I read with a great interest the letter from Salvatore and collaborators commenting on our article1 on the prognostic value of tumor sidedness in patients with stage III colon cancer from the PETACC-8 European trial and its relationship with BRAF and RAS mutational status. We found that while patients with RAS/BRAF wild-type right-sided tumors had a worse disease-free survival, patients with RAS/BRAF-mutant right-sided tumors had a significantly better disease-free survival in comparison with those with left-sided tumors.

Add or change institution